Galderma

About Galderma

Galderma is a global company focused on advancing dermatology for every skin story. They embrace individual skin differences and provide premium, cutting-edge solutions across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology to meet diverse skin needs.

Products & Services

Injectable Aesthetics:Products and solutions for aesthetic treatments using injectables.

Dermatological Skincare:Skincare products designed to address various dermatological needs.

Therapeutic Dermatology:Therapeutic solutions for treating skin conditions.

Brands:A portfolio of brands including Cetaphil, Restylane, Dysport, Sculptra, and others for aesthetics and dermatology.

Specialties

Injectable Aesthetics Dermatological Skincare Therapeutic Dermatology Skin Science Innovation in Dermatology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 1000000000 MR: - FA: approximately USD 1 billion FAN: 1000000000	D: 2023-06-26 FD: 2023-06-26	4 investors

Private Placement Latest

2023-06-26

$1.0B

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

Flemming Ørnskov

Chief Executive Officer

T

Thomas Dittrich

Chief Financial Officer

A

Adrian Murphy

Head of Global Operations

Recent News

Galderma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised